Effect of GnRH antagonists in FSH mildly stimulated intrauterine insemination cycles: A multicentre randomized trial

Piergiorgio G. Crosignani, E. Somigliana

Research output: Contribution to journalArticle

Abstract

Background: The usefulness of GnRH antagonists in mild controlled ovarian hyperstimulation (COH) and intrauterine insemination (IUI) cycles is debated. Methods: Two-hundred and ninety-nine couples with unexplained or mild male factor infertility were enrolled in this international multicentre randomized controlled trial. Women allocated to the GnRH antagonist group (n = 148) received 50 IU recombinant FSH starting on day 3 of the menstrual cycle and Ganirelix 0.25 mg daily starting from the day in which a follicle with a mean diameter of 13-14 mm was visualized at ultrasound. Women allocated to the control group (n = 151) were administered only 50 IU recombinant FSH starting on day 3 of the menstrual cycle. Couples were recruited only for their first treatment cycle. The primary outcome was the clinical pregnancy rate per initiated cycle. Results: Baseline characteristics of the two treatment groups were similar. Clinical pregnancy rates per initiated cycle in women who did and did not receive GnRH antagonists were 12.2 and 12.6%, respectively (P = 1.00). The relative risk of conception (95% confidence interval) for the use of GnRH antagonists was 1.0 (0.5-1.9). Conclusions: In mild COH and IUI cycles, any benefit of the use of GnRH antagonists in improving pregnancy rates is

Original languageEnglish
Pages (from-to)500-505
Number of pages6
JournalHuman Reproduction
Volume22
Issue number2
DOIs
Publication statusPublished - Feb 2007

Fingerprint

Insemination
Gonadotropin-Releasing Hormone
Multicenter Studies
Pregnancy Rate
Menstrual Cycle
Male Infertility
Randomized Controlled Trials
Confidence Intervals
Control Groups
Therapeutics

Keywords

  • GnRH antagonist
  • Intrauterine insemination
  • Mild ovarian hyperstimulation

ASJC Scopus subject areas

  • Physiology
  • Developmental Biology
  • Obstetrics and Gynaecology
  • Reproductive Medicine

Cite this

Effect of GnRH antagonists in FSH mildly stimulated intrauterine insemination cycles : A multicentre randomized trial. / Crosignani, Piergiorgio G.; Somigliana, E.

In: Human Reproduction, Vol. 22, No. 2, 02.2007, p. 500-505.

Research output: Contribution to journalArticle

@article{d27907def0e54bf0b495c442f5df9c69,
title = "Effect of GnRH antagonists in FSH mildly stimulated intrauterine insemination cycles: A multicentre randomized trial",
abstract = "Background: The usefulness of GnRH antagonists in mild controlled ovarian hyperstimulation (COH) and intrauterine insemination (IUI) cycles is debated. Methods: Two-hundred and ninety-nine couples with unexplained or mild male factor infertility were enrolled in this international multicentre randomized controlled trial. Women allocated to the GnRH antagonist group (n = 148) received 50 IU recombinant FSH starting on day 3 of the menstrual cycle and Ganirelix 0.25 mg daily starting from the day in which a follicle with a mean diameter of 13-14 mm was visualized at ultrasound. Women allocated to the control group (n = 151) were administered only 50 IU recombinant FSH starting on day 3 of the menstrual cycle. Couples were recruited only for their first treatment cycle. The primary outcome was the clinical pregnancy rate per initiated cycle. Results: Baseline characteristics of the two treatment groups were similar. Clinical pregnancy rates per initiated cycle in women who did and did not receive GnRH antagonists were 12.2 and 12.6{\%}, respectively (P = 1.00). The relative risk of conception (95{\%} confidence interval) for the use of GnRH antagonists was 1.0 (0.5-1.9). Conclusions: In mild COH and IUI cycles, any benefit of the use of GnRH antagonists in improving pregnancy rates is",
keywords = "GnRH antagonist, Intrauterine insemination, Mild ovarian hyperstimulation",
author = "Crosignani, {Piergiorgio G.} and E. Somigliana",
year = "2007",
month = "2",
doi = "10.1093/humrep/del416",
language = "English",
volume = "22",
pages = "500--505",
journal = "Human Reproduction",
issn = "0268-1161",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Effect of GnRH antagonists in FSH mildly stimulated intrauterine insemination cycles

T2 - A multicentre randomized trial

AU - Crosignani, Piergiorgio G.

AU - Somigliana, E.

PY - 2007/2

Y1 - 2007/2

N2 - Background: The usefulness of GnRH antagonists in mild controlled ovarian hyperstimulation (COH) and intrauterine insemination (IUI) cycles is debated. Methods: Two-hundred and ninety-nine couples with unexplained or mild male factor infertility were enrolled in this international multicentre randomized controlled trial. Women allocated to the GnRH antagonist group (n = 148) received 50 IU recombinant FSH starting on day 3 of the menstrual cycle and Ganirelix 0.25 mg daily starting from the day in which a follicle with a mean diameter of 13-14 mm was visualized at ultrasound. Women allocated to the control group (n = 151) were administered only 50 IU recombinant FSH starting on day 3 of the menstrual cycle. Couples were recruited only for their first treatment cycle. The primary outcome was the clinical pregnancy rate per initiated cycle. Results: Baseline characteristics of the two treatment groups were similar. Clinical pregnancy rates per initiated cycle in women who did and did not receive GnRH antagonists were 12.2 and 12.6%, respectively (P = 1.00). The relative risk of conception (95% confidence interval) for the use of GnRH antagonists was 1.0 (0.5-1.9). Conclusions: In mild COH and IUI cycles, any benefit of the use of GnRH antagonists in improving pregnancy rates is

AB - Background: The usefulness of GnRH antagonists in mild controlled ovarian hyperstimulation (COH) and intrauterine insemination (IUI) cycles is debated. Methods: Two-hundred and ninety-nine couples with unexplained or mild male factor infertility were enrolled in this international multicentre randomized controlled trial. Women allocated to the GnRH antagonist group (n = 148) received 50 IU recombinant FSH starting on day 3 of the menstrual cycle and Ganirelix 0.25 mg daily starting from the day in which a follicle with a mean diameter of 13-14 mm was visualized at ultrasound. Women allocated to the control group (n = 151) were administered only 50 IU recombinant FSH starting on day 3 of the menstrual cycle. Couples were recruited only for their first treatment cycle. The primary outcome was the clinical pregnancy rate per initiated cycle. Results: Baseline characteristics of the two treatment groups were similar. Clinical pregnancy rates per initiated cycle in women who did and did not receive GnRH antagonists were 12.2 and 12.6%, respectively (P = 1.00). The relative risk of conception (95% confidence interval) for the use of GnRH antagonists was 1.0 (0.5-1.9). Conclusions: In mild COH and IUI cycles, any benefit of the use of GnRH antagonists in improving pregnancy rates is

KW - GnRH antagonist

KW - Intrauterine insemination

KW - Mild ovarian hyperstimulation

UR - http://www.scopus.com/inward/record.url?scp=33846466750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846466750&partnerID=8YFLogxK

U2 - 10.1093/humrep/del416

DO - 10.1093/humrep/del416

M3 - Article

C2 - 17062582

AN - SCOPUS:33846466750

VL - 22

SP - 500

EP - 505

JO - Human Reproduction

JF - Human Reproduction

SN - 0268-1161

IS - 2

ER -